SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
148 hedge funds and large institutions have $1.7B invested in SpringWorks Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 46 reducing their positions, and 14 closing their positions.
6,095% more call options, than puts
Call options by funds: $6.88M | Put options by funds: $111K
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
20% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 46
8% more funds holding
Funds holding: 137 → 148 (+11)
0.52% less ownership
Funds ownership: 106.55% → 106.03% (-0.52%)
1% less capital invested
Capital invested by funds: $1.72B → $1.7B (-$15.9M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$42.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$35.8M |
| 3 |
DM
Deerfield Management
New York
|
+$16M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$15.3M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$9.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$51.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$27.6M |
| 3 |
O
OrbiMed
New York
|
-$22M |
| 4 |
PA
Perceptive Advisors
New York
|
-$15.7M |
| 5 |
Barclays
London,
United Kingdom
|
-$9.29M |
SWTX Hedge Fund Activity: Q1 2023 in Review
148 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2023, worth a combined $1.7B — down 0.92% from $1.72B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SWTX positions and 14 closed out — a net gain of 11 holders — while 55 added to existing stakes and 46 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $42.3M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $51.1M.
- 148 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2023, up from 137 in Q4 2022.
- Funds reported $1.7B of SpringWorks Therapeutics stock for Q1 2023, down 0.92% quarter-over-quarter.
- 25 funds opened new SpringWorks Therapeutics positions in Q1 2023 and 14 closed out, a net change of +11 holders.
- The largest SpringWorks Therapeutics buyer in Q1 2023 was Woodline Partners, an estimated $42.3M added.
- The largest SpringWorks Therapeutics seller in Q1 2023 was Bain Capital Life Sciences Investors, an estimated $51.1M sold.
Based on aggregated 13F filings for Q1 2023.